Psoriasis

ICD-11: EA90

Disease Overview

Psoriasis is a chronic immune-mediated skin disease characterized by hyperproliferation of keratinocytes, epidermal thickening, and inflammatory infiltrate. IL-23/Th17 axis is central; TNF and NF-κB pathways are therapeutic targets. Heritability ~60–70%; SNP-based h² ~0.28. Key genes include HLA-C*06:02, IL23R, and genes in the IL-23/Th17 pathway. Trauma, infection, stress, and medications can trigger flares. Comorbidities include psoriatic arthritis, cardiovascular disease, and metabolic syndrome.

Onset can occur in adolescence; psychosocial impact is substantial. UV and topical treatments are first-line.

Genetic Architecture Summary

GeneVariantGWAS pEvidenceStrength
HLA-Crs104845541.0e-100HLA-C*06:02 strongest risk allele; antigen presentation0.95
IL23Rrs112090261.0e-30IL-23 receptor; Th17 differentiation0.9

Heritability

h² SNP: 0.28 Psoriasis GWAS meta-analyses (2020)

PRS notes: PRS correlates with severity; transferability across ancestries limited.

Exposure Modifier Panel

ExposureDirectionStrengthConfidenceMechanism hypothesis
psychosocial-stressamplify0.75HIGH
uv-radiationbuffer0.7HIGHPhototherapy improves lesions

Population Equity Notes

GWAS ancestry breakdown: European-dominated discovery.

Transferability notes: HLA-C*06:02 replicated across ancestries; non-HLA loci vary.

Data gaps: Multi-ancestry GWAS and G×E.

Tissue Context

skin0.98
synovium0.60

Mechanism Brief Links

Visualizations

Risk Shift by Exposure Stratum

Population-level data only — does not predict individual risk

Tissue Relevance

References

  1. 1.Tsoi LC, et al. (2017). Psoriasis genome-wide association study. Nature Communications. doi:10.1038/s41467-017-01978-8
  2. 2.Armstrong AW, et al. (2021). Environmental triggers in psoriasis. JAMA Dermatology. doi:10.1001/jamadermatol.2020.4838